Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment ...

Eli Lilly (NYSE:LLY) shares dropped in price Wednesday, amid news the company is suing two pharmacies for compounding Zepbound and Mounjaro. Lilly claims the companies are skirting the Food and Drug ...

Several global studies, including the widely cited STEP 1 trial, have shown that discontinuing weight-loss medication often ...

Viking Therapeutics (NASDAQ: VKTX) is operating in one of the highest-growth pharma areas around. Viking doesn't sell weight ...

PVH Corp.’s (PVH) shares jumped 8.2% after the company reported adjusted earnings per share of $3.27, surpassing the Zacks Consensus Estimate of $3.19.Shares of Progress Software Corp. (PRGS) climbed ...

Shares of Hims & Hers closed 5.1% higher after the company said it will expand its weight-loss offerings with branded ...

The restoration of Mounjaro’s availability coincides with increasing competition in the GLP-1 space. Eli Lilly’s strategic moves to stabilise supply and invest in future capacity signal its ...

The telehealth company is offering Lilly’s branded form of tirzepatide—approved for weight loss—on its site for $1,899 a ...

Shares of Hims & Hers Health (NYSE: HIMS) surged on Tuesday, closing the session up 5.25% after having been up by as much as 14% earlier. The day's gain was powered by the telehealth company's ...